https://scholars.lib.ntu.edu.tw/handle/123456789/552804
標題: | ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients | 作者: | Chang, Gee-Chen Yang, Tsung-Ying Chen, Kun-Chieh Hsu, Kuo-Hsuan Huang, Yen-Hsiang KANG-YI SU SUNG-LIANG YU Tseng, Jeng-Sen |
公開日期: | 2020 | 卷: | 10 | 期: | 1 | 來源出版物: | Scientific reports | 摘要: | It remains unclear how programmed death-ligand 1 (PD-L1) expression interacts with anaplastic lymphoma kinase (ALK) mutation, its variants, and the outcome of treatment. One hundred and twenty four out of 1255 patients (9.9%) were deemed ALK-positive by the Ventana IHC assay. PD-L1 status and ALK variants were available in 100 and 59 patients, respectively. PD-L1 positive (TPS ≥ 1%) and strong positive (TPS ≥ 50%) rate was 50% and 16%, respectively. A total of 64 variant types were detected in 59 patients. V1 (32.8%) and V3a/b (28.1%) were the most common variants. There was no significant association between ALK variants and the PD-L1 expression. The presence of V3a/b subtype independently predicted a worse overall survival in patients receiving ALK inhibitor(s) (aHR 5.10 [95% CI 1.22-21.25], P = 0.025) and platinum plus pemetrexed (aHR 9.62 [95% CI 1.90-48.80], P = 0.006). While incorporating ALK variants and PD-L1 expression together, patients with non-V3a/b/positive PD-L1 showed a trend towards longer OS. In conclusion, ALK-positive NSCLC patients possess a high PD-L1 expression rate. Although there was no significant association between PD-L1 expression and ALK variants, the outcome of ALK-positive patients could be sorted by these two biomarkers. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/552804 | ISSN: | 2045-2322 | DOI: | 10.1038/s41598-020-78152-1 | SDG/關鍵字: | ALK protein, human; anaplastic lymphoma kinase; programmed death 1 ligand 1; adverse event; cigarette smoking; disease free survival; enzymology; female; genetics; human; lung tumor; male; middle aged; mutation; non small cell lung cancer; treatment outcome; Anaplastic Lymphoma Kinase; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cigarette Smoking; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Treatment Outcome |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。